timothy sykes logo
McKesson Corporation Clears European Hurdles and Raises FY26 EPS Guidance Thumbnail
ADD US ONG Google News

McKesson Corporation Clears European Hurdles and Raises FY26 EPS Guidance

ELLIS HOBBS•UPDATED FEB. 5, 2026, 5:04 PM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

McKesson Corporation stocks have been trading up by 16.52 percent driven by strategic partnerships advancing healthcare innovation.

  • The company revised its FY26 earnings per share (EPS) outlook to a range between $38.80 and $39.20, topping prior consensus estimate of $38.68, highlighting strong optimism for future gains.

  • Morgan Stanley has boosted McKesson’s price target from $916 to $966, maintaining its bullish stance on the stock with an “Overweight” rating.

  • Reporting stellar Q3 earnings, McKesson exceeded estimates with an adjusted EPS of $9.34 and revenue of $106.2 billion, driven by robust sales in its North American Pharmaceutical segment.

Candlestick Chart

Live Update At 17:03:50 EST: On Thursday, February 05, 2026 McKesson Corporation stock [NYSE: MCK] is trending up by 16.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In its most recent earnings report, McKesson showcased remarkable financial resilience. The company eclipsed expectations, reporting an adjusted EPS of $9.34 and an uplifting revenue figure of $106.2 billion. This performance is attributed mainly to significant growth in North American Pharmaceutical sales along with robust Oncology and Multispecialty sectors.

On a broader scale, McKesson’s key financial metrics reveal insightful trends. The enterprise value stands at $100.68 billion, underpinning its substantial market presence. Balance sheets reflect total assets amounting to $84.16 billion, while a return on assets at 2.09% suggests prudent utilization of its considerable capital. The management’s efficiency is underscored by a high inventory turnover ratio of 14.8, indicating effective inventory management within the firm’s complex supply chain.

From an income perspective, McKesson’s reported net income of $1.11 billion suggests consistent profitability. Moreover, a comprehensive glimpse at its financial strength uncovers a current ratio of 0.9, reflecting liquidity at a level that twin-tools flexibility with prudence.

The reported EPS guidance elevation in FY26 to $38.80-$39.20 from the earlier $38.35-$38.85 range, aligned with McKesson’s progressive revenue growth of 11% year-over-year. This mirrors the organization’s steadfast strategy in optimizing its core pharmaceutical and biopharma services, ensuring an advantageous position amidst evolving market dynamics.

Strategic Moves: Market Response

Delving deeper into McKesson’s noteworthy strategic maneuver in Europe, divestiture from its Norwegian arm, places the organization on a clear path to concentrating resources toward bolstering key growth avenues. As per recent updates, this decisive exit is synchronized with ambitious aspirations across Oncology, Multispecialty, and Biopharma Service domains — areas earmarked for exponential growth.

Moreover, investor sentiment significantly pivoted on McKesson’s recent upward earnings revision. The revised EPS target is a testament to proactive financial oversight and strategic vigilance, which is bolstered by robust fundamentals and market confidence.

Furthermore, the increase in price target to $966 reflects Wall Street’s confidence in McKesson’s stock, validated by a resounding “Overweight” rating from Morgan Stanley. This optimistic forecast underscores the financial institution’s trust in McKesson’s solid financial health and strategic execution.

More Breaking News

Conclusion

McKesson Corporation is on an upward trajectory, anchored by exemplary financial foresight and strategic realignment. The completion of its retail and distribution retreat from Europe signifies a pivotal shift in focus towards high-performing sectors that sustain its growth narrative. Coupled with a favorable FY26 earnings forecast and sustained trader confidence, the company is poised for continued success.

Traders are likely to view McKesson as a compelling prospect within its industry landscape. As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.” This philosophy is reflected as McKesson amplifies efforts to navigate and capitalize on emerging market trends. McKesson’s robust financial health supports an optimistic outlook amidst an evolving global marketplace.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MCK

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”